In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2006-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BMC.2006.07.055PMID 17399990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular and Clinical Advances in Anticancer Drug Resistance

  2012cited by this paper
• Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells

  2012cited by this paper
• Drug Resistance in Cancer Therapy

  2011cited by this paper
• In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450.

  2006cited by this paper
• Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.

  2006cited by this paper
• Phase III study of PSC‐833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95)

  2006cited by this paper
• The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).

  2006cited by this paper
• Mechanisms and strategies to overcome multiple drug resistance in cancer

  2006cited by this paper
• Territrems B and C metabolism in human liver microsomes: major role of CYP3A4 and CYP3A5.

  2006cited by this paper
• Modulation of Oral Drug Bioavailability: From Preclinical Mechanism to Therapeutic Application

  2005cited by this paper
• Modelling atypical CYP3A4 kinetics: principles and pragmatism.

  2005cited by this paper
• Tumoral drug metabolism: overview and its implications for cancer therapy.

  2005cited by this paper
• Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma

  2005cited by this paper
• P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing

  2005cited by this paper
• Immunosuppressors and reversion of multidrug-resistance.

  2005cited by this paper
• Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.

  2004cited by this paper
• The role of ABC transporters in drug resistance, metabolism and toxicity.

  2004cited by this paper
• An improved resazurin-based cytotoxicity assay for hepatic cells

  2004cited by this paper
• New multidrug resistance reversal agents.

  2003cited by this paper
• A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).

  2003cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate

  2002cited by this paper
• Mechanisms of cancer drug resistance.

  2002cited by this paper
• In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

  2001cited by this paper
• The drug efflux-metabolism alliance: biochemical aspects.

  2001cited by this paper
• Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.

  2000cited by this paper
• Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance

  2000cited by this paper
• Modulation of oral bioavailability of anticancer drugs: from mouse to man.

  2000cited by this paper
• P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.

  2000cited by this paper
• The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein

  1999cited by this paper
• Novel multidrug resistance reversal agents.

  1999cited by this paper
• Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.

  1999cited by this paper
• Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives.

  1999cited by this paper
• Taxol transport by human intestinal epithelial Caco-2 cells.

  1998cited by this paper
• Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

  1997cited by this paper
• Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

  1996cited by this paper
• Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

  1994cited by this paper
• In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

  1993cited by this paper
• Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin.

  1993cited by this paper
• Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing themdr1 phenotype

  1992cited by this paper
• Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype.

  1992cited by this paper
• High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine.

  1992cited by this paper
• Characteristics of Multidrug Resistance in Human Tumor Cells

  1991cited by this paper
• Modulators of P-glycoprotein-associated multidrug resistance.

  1991cited by this paper
• P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

  1991cited by this paper
• Analysis of multidrug resistance (MDR‐1) gene expression in chronic lymphocytic leukaemia (CLL)

  1991cited by this paper
• Drug resistance: the clinical problem.

  1989cited by this paper
• Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.

  1989cited by this paper
• Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

  1986cited by this paper
• Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance.

  1985cited by this paper
• Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells.

  1984cited by this paper
• Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.

  1983cited by this paper
• Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

  1981cited by this paper
• A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

  1976cited by this paper

• Novel hybrids of sclareol and 1,2,4-triazolo[1,5-a]pyrimidine show collateral sensitivity in multidrug-resistant glioblastoma cells.

  2023cites this paper
• The Tetrahydroisoquinoline Scaffold in ABC Transporter Inhibitors that Act as Multidrug Resistance (MDR) Reversers.

  2022cites this paper
• Systemic pharmacological investigation of the Feng Shi Gu Tong capsule in the treatment of rheumatoid arthritis

  2021cites this paper
• Role of endoplasmic reticulum stress in size-dependent inhibition of P-glycoprotein by silver nanoparticles in multidrug-resistant breast cancer cells

  2020cites this paper
• Chemical and pharmacological characterization of the TRPML calcium channel blockers ML-SI1 and ML-SI3.

  2020cites this paper
• Novel Quinoline Compound Derivatives of NSC23925 as Potent Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance

  2019cites this paper
• Selective, Catalytic, and Dual C(sp3)-H Oxidation of Piperazines and Morpholines under Transition-Metal-Free Conditions.

  2018cites this paper
• Design, synthesis and evaluation of a novel series of inhibitors reversing P‐glycoprotein‐mediated multidrug resistance

  2018cites this paper
• 15-0600-Dr. Fox’s response to letter to the editor

  2016cites this paper
• Antimicrobial and Immunosuppressive Activitities of Cyclopeptides as Targets for Medicinal Chemistry

  2016cites this paper
• The role of ABC transporters in ovarian cancer progression and chemoresistance.

  2015cites this paper
• Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.

  2015cites this paper
• Synthesis and anticancer activity of novel quinoline-docetaxel analogues.

  2014cites this paper
• Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?

  2014cites this paper
• Isolation, Structure Characterization, and Synthesis of Stabilized 1,2,3,4-Tetrahydroisoquinoline Marine Natural Product from Potassium Cyanide Pretreated Thai Tunicate, Ecteinascidia thurstoni.

  2014cites this paper
• Thieno[2,3-b]pyridines--a new class of multidrug resistance (MDR) modulators.

  2014cites this paper
• Activity-lipophilicity relationship studies on P-gp ligands designed as simplified tariquidar bulky fragments.

  2013cites this paper
• Prediction of Promiscuous P-Glycoprotein Inhibition Using a Novel Machine Learning Scheme

  2012cites this paper
• A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.

  2011cites this paper
• Quinoline as a privileged scaffold in cancer drug discovery.

  2011influential citation
• Application of cytochrome P450 drug interaction screening in drug discovery.

  2010cites this paper
• Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET

  2010influential citation
• Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials.

  2010cites this paper
• Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors.

  2010cites this paper
• A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine

  2009cites this paper
• Chemistry of Ring‐Fused Oxazine‐2,4‐diones

  2009cites this paper
• Traitement du cancer par le desthiazolyle ritonavir

  2009cites this paper
• Structure–Activity Relationships of Tariquidar Analogs as Multidrug Resistance Modulators

  2009cites this paper
• Preparation of nano-emulsified paclitaxel using MPEG–PLGA diblock copolymers

  2008cites this paper
• Preparation of Lipid Nanoparticles Containing Paclitaxel and their in vitro Gastrointestinal Stability

  2008cites this paper
• Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice

  2008cites this paper
• Tariquidar Analogues: Synthesis by CuI‐Catalysed N/O–Aryl Coupling and Inhibitory Activity against the ABCB1 Transporter

  2007cites this paper